{"nctId":"NCT01767519","briefTitle":"A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence","startDateStruct":{"date":"2013-03-01","type":"ACTUAL"},"conditions":["Overactive Bladder","Urinary Incontinence"],"count":356,"armGroups":[{"label":"BOTOX®","type":"EXPERIMENTAL","interventionNames":["Biological: BOTOX®","Drug: solifenacin placebo"]},{"label":"solifenacin","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: BOTOX®","Drug: solifenacin","Drug: Botox placebo (normal saline)"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: BOTOX®","Drug: Botox placebo (normal saline)","Drug: solifenacin placebo"]}],"interventions":[{"name":"BOTOX®","otherNames":["onabotulinumtoxinA","botulinum toxin Type A"]},{"name":"solifenacin","otherNames":["Vesicare"]},{"name":"Botox placebo (normal saline)","otherNames":[]},{"name":"solifenacin placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Symptoms of Overactive Bladder (OAB) (frequency/urgency) with urinary incontinence for at least 6 months\n* Inadequate response or limiting side effects with anticholinergics for the treatment of OAB\n\nExclusion Criteria:\n\n* Overactive Bladder caused by neurological condition\n* Patient has predominance of stress incontinence\n* Use of anticholinergics or other medications to treat OAB symptoms in the 7 days prior to screening\n* Previous use of solifenacin\n* History or evidence of pelvic or urological abnormality\n* Previous use of any botulinum toxin of any serotype for any urological condition\n* Previous use of any botulinum toxin of any serotype for any non-urological condition within 12 weeks of randomization\n* Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to the study visit in Treatment Cycle 1. The number of incontinence episodes are averaged daily during this period. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.86","spread":"3.206"},{"groupId":"OG001","value":"5.23","spread":"3.333"},{"groupId":"OG002","value":"4.38","spread":"2.485"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.10","spread":"2.799"},{"groupId":"OG001","value":"-2.66","spread":"3.059"},{"groupId":"OG002","value":"-0.98","spread":"2.417"}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With 100% Reduction in Incontinence Episodes in Treatment Cycle 1","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to the study visit in Treatment Cycle 1. The number of incontinence episodes are averaged daily during this period and compared to baseline to determine 100% reduction in episodes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":null},{"groupId":"OG001","value":"24.5","spread":null},{"groupId":"OG002","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With a Positive Response on the Single-Item Treatment Benefit Scale During Treatment Cycle 1","description":"A positive treatment response on the Treatment Benefit Scale is a score of either 1 or 2, representing 'greatly improved' or 'improved.'","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null},{"groupId":"OG001","value":"74.0","spread":null},{"groupId":"OG002","value":"44.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Number of Micturition Episodes in Treatment Cycle 1","description":"The number of micturition episodes (the number of times a patient urinates into the toilet) in Treatment Cycle 1 was recorded by the patient in a bladder diary during 3 consecutive days in the week prior to the visit. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.74","spread":"2.520"},{"groupId":"OG001","value":"10.40","spread":"2.665"},{"groupId":"OG002","value":"10.18","spread":"2.491"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.40","spread":"2.827"},{"groupId":"OG001","value":"-2.03","spread":"2.833"},{"groupId":"OG002","value":"-0.87","spread":"2.413"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Number of Nocturia Episodes in Treatment Cycle 1","description":"Nocturia episodes are measured over a 3 day diary prior to each visit in Treatment Cycle 1. A nocturia episode is a void (urinating into the toilet) that interrupts one's sleep. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"1.159"},{"groupId":"OG001","value":"2.04","spread":"1.083"},{"groupId":"OG002","value":"1.98","spread":"0.937"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"1.195"},{"groupId":"OG001","value":"-0.49","spread":"1.133"},{"groupId":"OG002","value":"-0.23","spread":"1.091"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Role Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1","description":"The King's Health Questionnaire is a disease-specific questionnaire that measures the quality of life of patients with urinary incontinence. The questionnaire consists of 7 domains, including the role limitations domain. Domain scores range from 0 to 100, with a lower score indicating a preferable health status. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.09","spread":"24.281"},{"groupId":"OG001","value":"72.11","spread":"26.581"},{"groupId":"OG002","value":"81.36","spread":"20.781"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.0","spread":"33.259"},{"groupId":"OG001","value":"-23.79","spread":"31.899"},{"groupId":"OG002","value":"-17.25","spread":"29.033"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Social Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1","description":"The King's Health Questionnaire is a disease-specific questionnaire that measures the quality of life of patients with urinary incontinence. The questionnaire consists of 7 domains, including the social limitations domain. Domain scores range from 0 to 100, with a lower score indicating a preferable health status. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.66","spread":"21.442"},{"groupId":"OG001","value":"56.22","spread":"22.708"},{"groupId":"OG002","value":"62.57","spread":"22.551"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.46","spread":"21.906"},{"groupId":"OG001","value":"-12.70","spread":"21.361"},{"groupId":"OG002","value":"-7.60","spread":"21.667"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":145},"commonTop":["Urinary tract infection","Bacteriuria","Dry mouth","Dysuria","Residual urine volume"]}}}